A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV

Steinbild S, Burkholder I, Edler L, Hanauske A, Hochhaus A, Strumberg D, Dittrich C, Gillessen Sommer S, Morant R, Frost A, Mross K, Scheulen M. A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. British journal of cancer 2007; 97:1480-5.